MARC Record from marc_columbia

LEADER: 05321fam a2200445 a 4500
001 4053120
005 20221027024943.0
008 960812s1996 ne a b 101 0 eng c
010 $a 96036161
020 $a0444824537 (alk. paper)
035 $a(OCoLC)59586008
035 $a(OCoLC)ocm59586008
035 $9ALZ6971HS
035 $a(NNC)4053120
035 $a4053120
040 $aDNLM/DLC$cDLC$dDLC$dNNC-M$dOrLoB-B
050 00 $aRC268.15$b.I57 1996
060 10 $aW3 EX89 no.1120 1996$aQZ 267 I4587s 1996
082 00 $a616.99/405$220
111 2 $aInternational Forum on the Scientific Bases of Cancer Chemoprevention$d(1996 :$cBologna, Italy)$0http://id.loc.gov/authorities/names/n96802528
245 14 $aThe scientific bases of cancer chemoprevention :$bproceedings of the International Forum on the Scientific Bases of Cancer Chemoprevention, 31 March-2 April 1996 /$ceditors, Cesare Maltoni, Morando Soffritti, Walter Davis.
260 $aAmsterdam ;$aNew York :$bElsevier,$c1996.
300 $axix, 290 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aInternational congress series ;$vno. 1120
504 $aIncludes bibliographical referencesand indexes.
505 00 $tThe Maria Theresa Chiantore Seragnoli Memorial Lecture: Public health control of cancer. An interim measure pending the discovery of the "magic pill" /$rN. Gray --$tThe potential of chemoprevention in cancer control /$rH. Vainio and P. Kleihues --$tImportance of genome modifications in carcinogenesis /$rA. Sarasin and L. Daya-Grosjean --$tGenetic instability and cancer /$rC. Ramel --$tDisturbances in cell cycle control as targets for cancer chemoprevention: the cyclin D1 paradigm /$rA. Sgambato, P. Zhou and N. Arber [et al.] --$tThe contribution of rodent liver and lung carcinogenesis models to our knowledge of the cancer latent period /$rT. R. Devereux, D. E. Malarkey and R. R. Maronpot --$tCurrent knowledge of the cancer latent period: chemoprevention strategies during colonic cancer development /$rM. Lipkin --$tCurrent knowledge about the cancer latent period: the contribution of epidemiology /$rJ. C. Bailar III --
505 80 $tThe contribution of epidemiology and molecular biology for identifying population groups eligible for cancer chemoprevention /$rG. J. Kelloff, C. W. Boone and W. F. Malone [et al.] --$tGenetic predisposition of susceptible groups to cancers /$rH. J. Evans --$tFundamental issues in chemoprevention /$rJ. Cuzick --$tIn vitro/ex vivo studies using primary cells of tumor target tissues for studying aspects of cancer prevention /$rB. L. Pool-Zobel --$tIn vivo studies, their strengths and weaknesses /$rR. Kroes --$tMethodology of intervention trials and programs for cancer prevention /$rH. Sancho-Garnier --$tVitamins, oligo-elements and cancer prevention: epidemiological evidence /$rP. van't Veer, E. Guallar and F. J. Kok [et al.] --$tPrevention of hormone-related cancers /$rB. E. Henderson --$tImmunological and other active agents /$rO. C. Leeksma, G. J. A. ten Bosch and C. J. M. Melief --
505 80 $tCarcinogenesis, endocrine risk factors and natural history of breast cancer /$rJ. G. M. Klijn, L. C. Verhoog and C. Brekelmans [et al.] --$tIdentification of women at high risk of breast cancer due to inherited susceptibility /$rD. E. Goldgar --$tExperimental results on the chemopreventive and side effects of tamoxifen using a human-equivalent animal model /$rC. Maltoni, F. Minardi and F. Belpoggi [et al.] --$tPsychological implications of tamoxifen treatment in women at high risk to breast cancer /$rL. Fallowfield --$tOngoing trials on the chemoprevention of breast cancer with tamoxifen /$rA. Costa, V. Sacchini and B. Bonanni [et al.] --$tExperimental studies on the chemopreventive effects of medroxyprogesterone acetate (MPA) on mammary cancer, using a human-equivalent animal model /$rF. Minardi, L. Bua and A. Santi [et al.] --
505 80 $tResults of experimental bioassays on the chemopreventive effects of vitamin A and N-(4-hydroxyphenil)-retinamide (HPR) on mammary cancer /$rM. Soffritti, A. Mobiglia and C. Pinto [et al.] --$tOngoing clinical chemoprevention study of breast cancer with fenretinide /$rG. De Palo, T. Camerini and E. Marubini [et al.] --$tAn overview of recent results of chemoprevention trials /$rE. Buiatti --$tCost-effectiveness analysis in chemoprevention of cancer: methodology /$rJ. D. F. Habbema --$tEthical issues of intervention trials in cancer /$rH. Sancho-Garnier and R. Joseph --$tChairman's summary and conclusion /$rC. G. Schmidt.
650 0 $aCancer$xChemoprevention$vCongresses.$0http://id.loc.gov/authorities/subjects/sh2009118235
650 12 $aChemoprevention.$0https://id.nlm.nih.gov/mesh/D018890
650 12 $aNeoplasms$xprevention & control.$0https://id.nlm.nih.gov/mesh/D009369Q000517
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
700 1 $aMaltoni, Cesare.$0http://id.loc.gov/authorities/names/n83125069
700 1 $aSoffritti, Morando.$0http://id.loc.gov/authorities/names/n96802527
700 1 $aDavis, Walter.$0http://id.loc.gov/authorities/names/nb2010011024
830 0 $aInternational congress series ;$vno. 1120.$0http://id.loc.gov/authorities/names/n42029631
852 00 $boff,hsl$hRC268.15$i.I57 1996